Application No.: 10/520,431

2

Docket No.: 57734(11259)

- Claims 26-38 are drawn to a method for tracking cells in vivo at any desired V. location.
- Claims 39-48 are drawn to a composition comprising an isolated and purified VI. cells vector encoding for a bispecific antibody and a fluorescent protein.
- Claims 49-52 are drawn to a method of using cells in functional assays, VII. wherein said assay is a T cell assay.
- Claims 49-51 and 53 are drawn to a method of using cells in functional VIII. assays, wherein said assay is an ELISA,RIA.
- Claims 49-51 and 53 are drawn to a method of using cells in functional IX. assays, wherein said assay is a cytokine assay.

Applicants respectfully request reconsideration of the Restriction Requirement as set forth. Please note, the search for Groups I and II overlap.

Applicants do not believe that any fee is due in connection with this response, however, if for any reason a fee is required, the Commissioner is hereby authorized and requested to charge Deposit Account No. 04-1105.

Dated: June 1, 2007

Respectfully submitted,

Kathryn A. Piffat, Ph.D. Registration No.: 34,901

EDWARDS ANGELL PALMER & DODGE

LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 439-4444

Attorneys/Agents For Applicant